JP2021533886A - 分解可能なデバイス上のポリマー層の改良 - Google Patents
分解可能なデバイス上のポリマー層の改良 Download PDFInfo
- Publication number
- JP2021533886A JP2021533886A JP2021507603A JP2021507603A JP2021533886A JP 2021533886 A JP2021533886 A JP 2021533886A JP 2021507603 A JP2021507603 A JP 2021507603A JP 2021507603 A JP2021507603 A JP 2021507603A JP 2021533886 A JP2021533886 A JP 2021533886A
- Authority
- JP
- Japan
- Prior art keywords
- degradable
- coating
- implant
- implant according
- growth inhibitory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000642 polymer Polymers 0.000 title description 15
- 238000000576 coating method Methods 0.000 claims abstract description 56
- 239000011248 coating agent Substances 0.000 claims abstract description 55
- 239000007943 implant Substances 0.000 claims abstract description 53
- 239000013543 active substance Substances 0.000 claims abstract description 49
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 34
- 229920006237 degradable polymer Polymers 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 8
- 229910000861 Mg alloy Inorganic materials 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 5
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 5
- 229910045601 alloy Inorganic materials 0.000 claims description 4
- 239000000956 alloy Substances 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 3
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 238000003618 dip coating Methods 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229960000235 temsirolimus Drugs 0.000 claims description 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 2
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 claims description 2
- 229950009819 zotarolimus Drugs 0.000 claims description 2
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims description 2
- 238000000354 decomposition reaction Methods 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 0 *C(C1CCCC1)=O Chemical compound *C(C1CCCC1)=O 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229910000640 Fe alloy Inorganic materials 0.000 description 2
- 229910001021 Ferroalloy Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229910001092 metal group alloy Inorganic materials 0.000 description 2
- 238000002161 passivation Methods 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
- A61L2300/608—Coatings having two or more layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/08—Coatings comprising two or more layers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
分解可能な本体;
少なくとも1つの分解可能なポリマーを含む第1の分解可能なコーティング;及び
増殖抑制活性物質。
シロリムス(CAS No.53123−88−9);
エベロリムス(CAS No.159351−69−6);
テムシロリムス(CAS No.162635−04−3);
リダホロリムス(CAS No.572924−54−0);
ゾタロリムス;又は
バイオリムスA9
からmTOR阻害剤が選択されることが提供される。
(ここで、RがC(O)−(CH2)n−Xであり、nが0、1又は2、Xが任意で1つ以上の不飽和結合を含む3〜9個の炭素原子を有する環状炭化水素である)
であることが提供される。
マグネシウム又はマグネシウム合金で作製された分解可能な本体;
0.7dl/gから1.2dl/gの範囲の分子量を有するポリ(L−乳酸)を含む、又は、からなる第1の分解可能なコーティング;及び
増殖抑制活性物質、好ましくは本願明細書に記載の式Iの活性物質
を含むことが提案される。
鉄又は鉄合金で作製された分解可能な本体;
0.9dl/gから3.8dl/g の範囲の分子量を有するポリ(L−乳酸)を含む、又は、からなる第1の分解可能なコーティング;及び
増殖抑制活性物質、好ましくは本願明細書に記載の式Iの活性物質
を含むことが提案される。
分解可能な本体を提供する工程;
少なくとも1つの分解可能なポリマーを含む第1の分解可能なコーティングを実質的に分解可能な本体の表面全体に適用する工程;及び
増殖抑制活性物質を本体の反管腔側の側面の第1の分解可能なコーティングに適用する工程。
マグネシウム又はマグネシウム合金で作製された分解可能な本体;
0.7dl/gから1.2dl/gの範囲のインヘレント粘度を有するポリ(L−乳酸)を含む、又は、からなる第1の分解可能なコーティング;及び
増殖抑制活性物質、好ましくは本願明細書に記載の式Iの活性物質
を含むことが提案される。
鉄又は鉄合金で作製された分解可能な本体;
0.9dl/gから3.8dl/g の範囲のインヘレント粘度を有するポリ(L−乳酸)を含む、又は、からなる第1の分解可能なコーティング;及び
増殖抑制活性物質、好ましくは本願明細書に記載の式Iの活性物質
を含むことが提案される。
Claims (11)
- 分解可能な本体(1);
少なくとも1つの分解可能なポリマーを含む第1の分解可能なコーティング(4);及び
増殖抑制活性物質(5)を含み、
第1の分解可能なコーティング(4)が、実質的に完全に本体(1)を取り囲み、及び
増殖抑制活性物質(5)が、本体(1)の反管腔側の側面(2)の第1の分解可能なコーティング(5)のみに適用される、インプラント。 - 第1の分解可能なコーティング(4)が、ポリ乳酸及び/又はポリ(ラクチド−co−グリコリド)及び/又はポリ−ε−カプロラクトンを含む、又は、から実質的になる、請求項1に記載のインプラント。
- 増殖抑制活性物質(5)が、mTOR阻害剤又は細胞増殖抑制剤、特にパクリタキセルである、請求項1又は2に記載のインプラント。
- 第1のコーティング(4)が、0.5dl/gから4.0dl/gの範囲のインヘレント粘度を有するポリ(L−乳酸)を含む、又はから実質的に成る請求項1〜4のいずれか1項に記載のインプラント。
- 本体(1)が、分解可能な金属から実質的に成る、又は分解可能な合金の形態において分解可能な金属を含む、請求項1〜5のいずれか1項に記載のインプラント。
- 本体(1)が、マグネシウム又は分解可能なマグネシウム合金を含む、又はから実質的になる、請求項1〜6のいずれか1項に記載のインプラント。
- 本体(1)が、空洞の円筒のメッシュの形態である、請求項1〜7のいずれか1項に記載のインプラント。
- インプラントが血管内のインプラント、特にステントである、請求項1〜8のいずれか1項に記載のインプラント。
- 請求項1〜9のいずれか1項に記載のインプラントを作製する方法であって、
分解可能な本体を提供する工程、
少なくとも1つの分解可能なポリマーを含む第1の分解可能なコーティングを実質的に分解可能な本体の表面全体に適用する工程、
増殖抑制活性物質を本体の反管腔側の第1の分解可能なコーティングに適用する工程
を含む、上記方法。 - 第1の分解可能なコーティング及び/又は増殖抑制活性物質がスプレー、アトマイジング(atomizing)、ディップコーティング(dip−coating)又はピペッティング(pipetting)によって適用される、請求項10に記載のインプラントを作製する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18190387.3 | 2018-08-23 | ||
EP18190387.3A EP3613449A1 (de) | 2018-08-23 | 2018-08-23 | Verbesserung der polymerschicht bei degradierbaren vorrichtungen |
PCT/EP2019/071832 WO2020038800A1 (en) | 2018-08-23 | 2019-08-14 | Improving the polymer layer on degradable devices |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021533886A true JP2021533886A (ja) | 2021-12-09 |
Family
ID=63371526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021507603A Pending JP2021533886A (ja) | 2018-08-23 | 2019-08-14 | 分解可能なデバイス上のポリマー層の改良 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210252198A1 (ja) |
EP (2) | EP3613449A1 (ja) |
JP (1) | JP2021533886A (ja) |
CN (1) | CN112368030A (ja) |
WO (1) | WO2020038800A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220354607A1 (en) | 2021-05-10 | 2022-11-10 | Cilag Gmbh International | Packaging assemblies for surgical staple cartridges containing bioabsorbable staples |
JP2024518074A (ja) | 2021-05-10 | 2024-04-24 | シラグ・ゲーエムベーハー・インターナショナル | コーティングを備える吸収性外科用ステープル |
JP2024518072A (ja) | 2021-05-10 | 2024-04-24 | シラグ・ゲーエムベーハー・インターナショナル | 吸収性ステープルを備える外科用ステープルカートリッジのシステム |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120035716A1 (en) * | 2010-08-03 | 2012-02-09 | Bjoern Klocke | Polylactide-coated implant composed of a biocorrodible magnesium alloy |
US20140193569A1 (en) * | 2007-09-28 | 2014-07-10 | Abbott Cardiovascular Systems Inc. | Stent with preferential coating |
WO2018046238A1 (de) * | 2016-09-08 | 2018-03-15 | Karl Leibinger Medizintechnik Gmbh & Co. Kg | Implantat mit calciumsalz-enthaltendem verbundpulver mit mikrostrukturierten teilchen |
WO2018046276A1 (de) * | 2016-09-08 | 2018-03-15 | Karl Leibinger Medizintechnik Gmbh & Co. Kg | Implantat enthaltend inhibierendes calciumcarbonat |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020143284A1 (en) * | 2001-04-03 | 2002-10-03 | Hosheng Tu | Drug-releasing trabecular implant for glaucoma treatment |
JP2005525911A (ja) * | 2002-05-20 | 2005-09-02 | オーバス メディカル テクノロジーズ インク. | 移植可能な薬物溶出医療用デバイス |
US7632307B2 (en) * | 2004-12-16 | 2009-12-15 | Advanced Cardiovascular Systems, Inc. | Abluminal, multilayer coating constructs for drug-delivery stents |
WO2006110487A1 (en) * | 2005-04-08 | 2006-10-19 | Surmodics, Inc. | Sustained release implants for subretinal delivery |
ZA200904416B (en) * | 2007-01-30 | 2010-08-25 | Hemoteq Ag | Biodegradable vascular support |
EP2407184A3 (de) * | 2010-07-16 | 2014-10-29 | Biotronik AG | Abluminal beschichtete Wirkstoff-freisetzende Stents mit einer formschlüssigen Schutzschicht |
US10098765B2 (en) * | 2010-12-15 | 2018-10-16 | Biotronik Ag | Implant and method for producing the same |
US9566367B2 (en) * | 2011-08-15 | 2017-02-14 | Helmholtz-Zentrum Geesthacht Zentrum fur Material-und Kustenforschung GmbH | Magnesium alloy and resorbable stents containing the same |
EP3120877A1 (en) * | 2015-07-24 | 2017-01-25 | B. Braun Melsungen AG | Endoluminal device |
JP7074747B2 (ja) * | 2016-09-19 | 2022-05-24 | バイオトロニック アクチェンゲゼルシャフト | ポリマーフリー薬剤溶出型血管ステント |
-
2018
- 2018-08-23 EP EP18190387.3A patent/EP3613449A1/de not_active Withdrawn
-
2019
- 2019-08-14 WO PCT/EP2019/071832 patent/WO2020038800A1/en unknown
- 2019-08-14 US US17/260,893 patent/US20210252198A1/en active Pending
- 2019-08-14 JP JP2021507603A patent/JP2021533886A/ja active Pending
- 2019-08-14 CN CN201980045711.1A patent/CN112368030A/zh active Pending
- 2019-08-14 EP EP19752524.9A patent/EP3840792B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140193569A1 (en) * | 2007-09-28 | 2014-07-10 | Abbott Cardiovascular Systems Inc. | Stent with preferential coating |
US20120035716A1 (en) * | 2010-08-03 | 2012-02-09 | Bjoern Klocke | Polylactide-coated implant composed of a biocorrodible magnesium alloy |
WO2018046238A1 (de) * | 2016-09-08 | 2018-03-15 | Karl Leibinger Medizintechnik Gmbh & Co. Kg | Implantat mit calciumsalz-enthaltendem verbundpulver mit mikrostrukturierten teilchen |
WO2018046276A1 (de) * | 2016-09-08 | 2018-03-15 | Karl Leibinger Medizintechnik Gmbh & Co. Kg | Implantat enthaltend inhibierendes calciumcarbonat |
Also Published As
Publication number | Publication date |
---|---|
EP3840792A1 (en) | 2021-06-30 |
EP3613449A1 (de) | 2020-02-26 |
US20210252198A1 (en) | 2021-08-19 |
CN112368030A (zh) | 2021-02-12 |
WO2020038800A1 (en) | 2020-02-27 |
EP3840792B1 (en) | 2022-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11793911B2 (en) | Stent made of a bio-degradable magnesium alloy with a magnesium fluoride coating and an organic coating | |
RU2360646C2 (ru) | Эндолюминальный протез, содержащий лечебное средство | |
US9522219B2 (en) | Resorbable stents which contain a magnesium alloy | |
EP1979013B1 (en) | Coated medical devices and methods of making the same | |
US20050137683A1 (en) | Medical devices to treat or inhibit restenosis | |
MX2010007571A (es) | Endoprotesis eluyente con receptaculo de rapamicina. | |
JP5385785B2 (ja) | メラトニンとパクリタキセルとの組合せを備えた医療用ステント | |
JP2009525809A (ja) | 表面浸食性ポリエステルによる薬剤送達コーティングを備える埋め込み式医療デバイス | |
EP3840792B1 (en) | Improving the polymer layer on degradable devices | |
US20100119578A1 (en) | Extracellular matrix modulating coatings for medical devices | |
CA2814653C (en) | Bare metal stent with drug eluting reservoirs having improved drug retention | |
US20080281409A1 (en) | Stents with drug eluting coatings | |
JP2009514623A (ja) | 腫瘍壊死因子−アルファ阻害剤を備えた医療用ステント | |
US20120150282A1 (en) | Implant having a paclitaxel-releasing coating | |
US20120239140A1 (en) | Medical product comprising an active coating | |
EP1523345A1 (en) | Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis | |
US20220241467A1 (en) | Stent with immediately removeable coating | |
KR20150137566A (ko) | 재협착과 염증 조절을 위한 순차적 약물 방출 스텐트의 제조방법 | |
US20090228097A1 (en) | A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device | |
Rastogi et al. | Drug eluting stents and beyond | |
JP2002193838A (ja) | 体内埋め込み医療材料および体内埋め込み医療器具 | |
Uurto | Preclinical Evaluation of New Drug-Eluting Biodegradable Poly-D/L-lactic Acid Vascular Stent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210225 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220714 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230421 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230428 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230721 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230921 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240416 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240424 |